Pharmaceutics (Nov 2021)

Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges

  • Md. Rizwanullah,
  • Mohammad Zaki Ahmad,
  • Mohammed M. Ghoneim,
  • Sultan Alshehri,
  • Syed Sarim Imam,
  • Shadab Md,
  • Nabil A. Alhakamy,
  • Keerti Jain,
  • Javed Ahmad

DOI
https://doi.org/10.3390/pharmaceutics13122039
Journal volume & issue
Vol. 13, no. 12
p. 2039

Abstract

Read online

Breast cancer therapeutic intervention continues to be ambiguous owing to the lack of strategies for targeted transport and receptor-mediated uptake of drugs by cancer cells. In addition to this, sporadic tumor microenvironment, prominent restrictions with conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer cells possess a big challenge to even otherwise optimal and efficacious breast cancer treatment strategies. Surface-modified nanomedicines can expedite the cellular uptake and delivery of drug-loaded nanoparticulate constructs through binding with specific receptors overexpressed aberrantly on the tumor cell. The present review elucidates the interesting yet challenging concept of targeted delivery approaches by exploiting different types of nanoparticulate systems with multiple targeting ligands to target overexpressed receptors of breast cancer cells. The therapeutic efficacy of these novel approaches in preclinical models is also comprehensively discussed in this review. It is concluded from critical analysis of related literature that insight into the translational gap between laboratories and clinical settings would provide the possible future directions to plug the loopholes in the process of development of these receptor-targeted nanomedicines for the treatment of breast cancer.

Keywords